The significance of health care research and real-world data has become increasingly obvious in recent years: numerous scientific and practice-oriented questions can be answered with high-quality registry data. iOMEDICO launched the first tumor registry back in 2006. Since then, an extensive real world data base has been build, which is unique in its scope, in-depths characterizations of patient paths, longterm observational data and real-world data expertise.
Their representativity and independence make our network registries an often-quoted basis for the actual health care service landscape in Germany. They form the foundation for more than 200 publications and presentations and are published and presented by participants of the network nationally as well as internationally.
Registry platforms with patient-reported outcomes
Patient-reported outcomes (PRO) are a crucial aspect in the evaluation of oncological therapies. They capture the patient’s perspective, which is often not recorded through clinical parameters. Correlations between therapy data and data on quality-of-life data provide information on patient-relevant endpoints.
Registry platforms systematically expand the real world data of tumor registries by patient-reported outcome data, biobanks and additional satellite projects. In 2015, iOMEDICO launched the first registry platform CRISP (AIO-TRK-0315) for lung cancer. Further projects such as OPAL (breast cancer), CARAT (renal cell carcinoma) and MYRIAM (Multiple Myeloma) followed.
For study sites: One setup – all the registries – all the results
Take advantage of the expertise and professional management of the health care research projects. The PAN registry project allows you to recruit patients from different entities into all active registries with just one set-up.
As a partner of the academically oriented registry group you will receive the latest analyses to include in your own presentations. As a medical advisor you can submit research questions for new analyses and participate in the projects as an author of publications.
Benefit assessment with high-quality data
Real world data are highly relevant for benefit assessments. They supplement clinical trial data and enable comprehensive evaluation. So far, the development of new therapy options has concentrated on clinicial efficacy and safety, now the focus is also on additional, complementary parameters.
It is only possible to harness the potential of the data through high-quality design and conduct in conjunction with meticulous connection and analysis of the data by real world data experts. Preparation and interpretation are time consuming and requires sound knowledge of methods. Our 17 years of experience guarantee a high level of expertise in all areas. High-quality health care research is a challenge we gladly accept.